cathvision

The ECGenius system. [Image from CathVision]CathVision announced that it received FDA clearance for its PVI Analyzer and Signal Complexity algorithms.

The algorithms, as part of the suite of AI-powered analytics, integrate into CathVision’s ECGenius system. ECGenius, an electrophysiology (EP) recording system for facilitating electrogram interpretation, helps physicians improve ablation outcomes. It delivers intelligent, automated analyses for complex atrial arrhythmia procedures by measuring the success of cardiac ablation.

Unlike traditional EP recording systems that capture signals affected by noise and artifact, CathVision says ECGenius delivers a necessary evolution in quality for ECG signal acquisition. It also enhances the accuracy of electrogram interpretation and the advancement of therapy support, according to a news release. The system’s intelligent, automated analyses can help physicians confirm the success of ablation efforts.

Copen…

[Image from CathVision]Electrophysiology (EP) technology developer CathVision announced today that it secured $7.2 million in funding from existing investors.

Copenhagen, Denmark-based CathVision plans to use the funds to advance commercial operations for driving the adoption of its ECGenius system for EP recording. Additionally, funds are earmarked for the development of artificial intelligence (AI)-powered analytic modules to provide electrophysiologists with automated analysis during cardiac ablation procedures.

“Our investors have witnessed the evolution of our company and technology in recent years,” Mads Matthiesen, CathVision CEO, said in a news release. “Reinvesting in the company demonstrates confidence in our innovation, ongoing development, and ability to advance adoption of the ECGenius System throughout the United States as we focus on empowering physicians to diagnose, characterize, and treat cardiac arrhythmias more effectively. We are expanding our…